(TheNewswire)
VANCOUVER, BC – TheNewswire- August 25, 2022 - AREV LIFE SCIENCES GLOBALCORP. (CSE:AREV) (CNSX:AREV.CN) (OTC:AREVF) (“AREV” or the “Company”) AREV LifeSciences Global Corporation announces today the coverage of in HealthHIV.org Article titled AnotherHorseman. The article can be read at https://healthhiv.org/resource/another-horseman/ .
The article articulates the need to aggressivelyaddress the use of Ready to Use Therapeutic Foods to treat Serious& Acute Malnutrition in PEPFAR and Global Fund recipient low &middle income countries (LMIC’s).
“ The global famine isundermining the efficacy of treatment for infectious diseases in theGlobal South and eastern Europe, and the data shown by key opinionleaders at AIDS 2022 and in this article demonstrates that clinicalnutrition, including RUTF’s can be transformative in patientoutcomes ” stated Mike Withrow CEO of AREV. Hewent on to say, “ Weapplaud HealthHIV for addressing the global challenge facing thestaggering growth of HIV patients facing food insecurity, malnutritionand SAM in the Global South.
SUSTAINN (Superior Utility Supplementation TherapeuticAgent for Indicated Nutritional Needs) is a next generation RUTF beingdeveloped by AREV Life Sciences, based in Vancouver. This initiativeaims to demonstrate the delivery of measurable therapeutic effect inforthcoming inferiority/superiority studies through a uniquenext-generation RUTF composition. SUSTAINN is intended to treatinanition, the complex disease state that is currently the culprit inthe deaths of nine million people worldwide annually, more than thedeath toll of AIDS, malaria, and tuberculosis combined. Inanition isclinically characterized by dysbiosis, environmental enteropathy,neurodegenerative disease, organ failure, scurvy, beriberi,Kwashiorkor, and anemia due to SAM.
SUSTAINN is being developed in collaboration with TheRichardson Centre for Food Technology and Research, University ofManitoba, TransBiotech, and key opinion leaders in biology,therapeutic development and clinical study design from the Instituteof Human Virology, University of Maryland and The Linus Pauling Centerat Oregon State University, is in compliance with WHO, andCodex-Alimentarious guidelines in 43 countries. RUTF’s are essentialtherapeutic interventions for the treatment of severe acutemalnutrition and currently account for more than US $440M in 2022 insales by more than 40 companies. SUSTAINN is being produced under GMPconditions, which meet relevant export criteria, is aflatoxin free anddesigned to maintain a shelf life of up to two years under appropriatestorage instructions. SUSTAINN provides optimal nutritional supportaddressing the restoration of gut microbiota, malabsorption associatedwith cachexia, provides essential nutrition, vitamin s, minerals and protein thatencourage muscle retention, and metabolic functions including ATPlevels and EFA supplementation that encourages neurologicaldevelopment. Further collaborations are in development followingmeetings at AIDS 2022 with AREV Executive leadership and key opinionleaders in positions of program leadership at PEPFAR, the Global Fundfor AIDS TB and Malaria, UNAIDS USAID and the World FoodProgram.
Innovations in RUTFs have demonstrated significantclinical benefits. Supporting neurological growth and function throughthe provision of essential fatty acids ( “ EFA ”) in SAMpatients was studied in a randomized, triple-blinded, controlledclinical trial by Wiley and published in the British Journal of Nutrition. This trial demonstrated that DHA Omega-3 supplements boostcognition in malnourished Malawian children. Low linoleic acid foodswith added DHA given to Malawian children with severe acutemalnutrition to improve cognition. Additional innovations utilizingprobiotics to restore microbiome in SAM patients have demonstratedsignificant improvements in dysbiosis and enteropathy, two clinicalpresentations that contribute to malabsorption syndrome, involuntaryweight loss and subsequent drug resistance.
The Company is also pleased toannounce it has settled $83,331.12 in debt with Chiron Capital Inc, aCompany wholly owned by a Director of the Company, by the issuance of595,222 Shares at $0.14.
Participation of the insiders of the Company in theshares for debt constitutes a related party transaction as definedunder Multilateral Instrument 61-101 (Protection of Minority SecurityHolders in Special Transactions). Because the Company’s shares tradeonly on the CSE, the issuance of securities is exempt from the formalvaluation requirements of Section 5.4 of MI 61-101 pursuant toSubsection 5.5(b) of MI 61-101 and exempt from the minority approvalrequirements of Section 5.6 of MI 61-101 under 5.7(b).
For further information, contact Mike Withrow,mike@AREVBrands.com 778-929-6536. For more informationvisit https://www.arevlifesciences.com/.
On behalf of the Board,
Mike Withrow
CEO & Director
About HealthHV
HealthHIV is a national non-profit working withorganizations, communities, and health care providers to advanceeffective prevention, care, and support for people living with, or atrisk for, HIV and HCV through education and training, technicalassistance and capacity building, advocacy, and health servicesresearch and evaluation. HealthHIV leads the HealthHCV initiative, theNational Center for Health Care Capacity Building, and the NationalCoalition for LGBTQ Health. Learn more at HealthHIV.org .
About AREV Life Sciences GlobalCorp.
The Company is a fully integrated enterprise withcompetencies in: 1) extraction of compounds for consumption andtopical use. 2) Clinical Nutrition and 3) A technology platform calledMedicine Merchant. The Company produces ingredients and formulatesexclusive therapeutic interventions with plans to deliver innovationin clinical nutrition, proprietary supplements, topicals and rationaldrug design, based on science. The Company’s business modelleverages its core competency of extraction to produce ingredients andcompounds for its pipeline of products. The Company continues in theproduct development and pre-commercialization stage.
AREV is dedicated to designing and deliveringinnovation in rational drug design, driven by presenting globalepidemiological characteristics of multiple challenges tointernational human and animal health. AREV is a member of bothBIOTECanada and The Biotechnology Innovation Organization (BIO).
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITSREGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITYFOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
Neither the Canadian Securities Exchange nor itsRegulation Services Provider (as that term is defined in policies ofthe CSE) accepts responsibility for the adequacy or accuracy of thisrelease. This news release may include forward-looking statements thatare subject to risks and uncertainties. All statements within, otherthan statements of historical fact, are to be considered forwardlooking. Although the Company believes the expectations expressed insuch forward looking statements are based on reasonable assumptions,such statements are not guarantees of future performance and actualresults or developments may differ materially from those inforward-looking statements. Factors that could cause actual results todiffer materially from those in forward-looking statements includemarket prices, exploitation and exploration successes, and continuedavailability of capital and financing, and general economic, market orbusiness conditions. There can be no assurances that such statementswill prove accurate and, therefore, readers are advised to rely ontheir own evaluation of such uncertainties. We do not assume anyobligation to update any forward-looking statements except as required
under the applicable laws. This press release containsforward-looking statements. The use of any of the words"anticipate", "continue", "estimate","expect", "may", "will","project", "should", "believe" andsimilar expressions are intended to identify forward-lookingstatements. Although the Company believes that the expectations andassumptions on which the forward-looking statements are based arereasonable, undue reliance should not be placed on the forward-lookingstatements because the Company can give no assurance that they willprove to be correct. Since forward-looking statements
address future events and conditions, by their verynature they involve inherent risks and uncertainties. These statementsspeak only as of the date of this press release. Actual results coulddiffer materially from those currently anticipated due to a number offactors and risks various risk factors discussed in theCompany’ s Management ’sDiscussion and Analysis under the Company’s profile on www.sedar.com.
Copyright (c) 2022 TheNewswire - All rights reserved.